NewLink Genetics Corp (NASDAQ:NLNK)

53.94
Delayed Data
As of Apr 01
 -0.77 / -1.41%
Today’s Change
17.32
Today|||52-Week Range
57.63
+35.70%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.6B

Company Description

NewLink Genetics Corp. is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. The company's product are: HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Contact Information

NewLink Genetics Corp.
2503 South Loop Drive
Ames Iowa 50010
P:(515) 296-5555
Investor Relations:

Employees

Shareholders

Individual stakeholders29.06%
Mutual fund holders25.21%
Other institutional21.56%

Top Executives

Charles J. LinkChairman, Chief Executive & Scientific Officer
Nicholas N. VahanianPresident & Chief Medical Officer
John B. HennemanChief Financial Officer & Executive Vice President
W. Jay RamseyClinical & Regulatory Compliance Officer
Brian WileyVice President-Business Development

To view my watchlist

Not a member yet?

Sign up now for a free account